Yale Head and Neck SPORE Publications

• Postoperative Radiotherapy ± Cetuximab for Intermediate-Risk Head and Neck Cancer.Machtay M, Torres-Saavedra PA, Thorstad W, Nguyen-Tân PF, Siu LL, Holsinger FC, El-Naggar A, Chung C, Cmelak A, Burtness B, Bednarz G, Quon H, Breen SL, Gwede CK, Dicker AP, Yao M, Jordan RC, Dorth J, Lee N, Chan JW, Dunlap N, Bar-Ad V, Stokes WA, Chakravarti A, Sher D, Rao S, Harris J, Yom SS, Le QT. J Clin Oncol. 2025 Apr 20; 2025 Jan 22. PMID: 39841939.
• Neoadjuvant chemotherapy and surgery versus surgery for organ preservation of T3 and T4a nasal and paranasal sinus squamous cell carcinoma (NPNSCC) ECOG-ACRIN EA3163.Saba NF, Flamand Y, Lin DT, Chung CH, McDonald MW, Flampouri S, Khan SA, Snyderman CH, Hanna EY, El-Sayed IH, Solares CA, Le CH, Ghaly M, Hwang PH, Shin DM, Axelrod RS, Ikpeazu CV, Adkins DR, Duan F, Cohen M, Samuels MA, Swiecicki PL, Subramaniam RM, Chakravarthy AB, Burtness BA. Clin Cancer Res. 2025 Apr 14; 2025 Apr 14. PMID: 40227186.
• HER2 testing: evolution and update for a companion diagnostic assay.Robbins CJ, Bates KM, Rimm DL. Nat Rev Clin Oncol. 2025 Apr 7; 2025 Apr 7. PMID: 40195456.
• Phase II Trial of Chemotherapy, Cetuximab, and Erlotinib in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck.Bhatia A, Mehra R, Bauman J, Khan SA, Wei W, Neumeister V, Sandoval-Schaefer T, Alpaugh RK, Lango M, Rimm DL, Ridge JA, Burtness B. Head Neck. 2025 Apr 1; 2025 Apr 1. PMID: 40166973.
• Financial Compensation of Academic Otolaryngologists in the United States: Trends and Distribution.Shah R, Tyagi S, Futela D, Malhotra A, Judson BL. Laryngoscope. 2025 Apr; 2024 Nov 12. PMID: 39530275.
• Machine learning-based spatial characterization of tumor-immune microenvironment in the EORTC 10994/BIG 1-00 early breast cancer trial.Zerdes I, Matikas A, Mezheyeuski A, Manikis G, Acs B, Johansson H, Boyaci C, Boman C, Poncet C, Ignatiadis M, Bai Y, Rimm DL, Cameron D, Bonnefoi H, Bergh J, MacGrogan G, Foukakis T. NPJ Breast Cancer. 2025 Mar 7; 2025 Mar 7. PMID: 40055382.
• Quantitative Protein Expression of Antibody-Drug Conjugate Targets in EGFR Mutated and Wild-Type Non-Small Cell Lung Cancer.Trontzas IP, He M, Wurtz A, Robbins CJ, Robinson N, Bates K, Liu M, Aung TN, Scott L, Chan N, Burela S, Schillo J, Liebler DC, Hill S, Morrison RD, Vathiotis I, Syrigos KN, Goldberg SB, Politi K, Rimm DL. Clin Cancer Res. 2025 Mar 6; 2025 Mar 6. PMID: 40047548.
• Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach.Lopez de Rodas M, Villalba-Esparza M, Sanmamed MF, Chen L, Rimm DL, Schalper KA. Nat Rev Clin Oncol. 2025 Mar; 2025 Jan 16. PMID: 39820025.
• The widespread application of trans-oral robotic surgery in HPV-related head and neck cancer: one size does not fit all.Patel MR, Burtness B, Ferris RL, Saba NF. J Natl Cancer Inst. 2025 Mar 1. PMID: 39699215.
• Loss of JAK1 Function Causes G2/M Cell Cycle Defects Vulnerable to Kif18a Inhibition.Kelley V, Baro M, Gasperi W, Ader N, Lea H, Lee H, Phoomak C, Kabeche L, King M, Contessa J. bioRxiv. 2025 Feb 24; 2025 Feb 24. PMID: 40060568.
• The role of surgery and deescalation for HPV-related oropharyngeal cancer.Contrera KJ, Patel MR, Burtness B, Mehra R, Ferris RL. Cancer. 2025 Jan 15; 2024 Mar 18. PMID: 38497569.
• Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing.Taube JM, Sunshine JC, Angelo M, Akturk G, Eminizer M, Engle LL, Ferreira CS, Gnjatic S, Green B, Greenbaum S, Greenwald NF, Hedvat CV, Hollmann TJ, Jiménez-Sánchez D, Korski K, Lako A, Parra ER, Rebelatto MC, Rimm DL, Rodig SJ, Rodriguez-Canales J, Roskes JS, Schalper KA, Schenck E, Steele KE, Surace MJ, Szalay AS, Tetzlaff MT, Wistuba II, Yearley JH, Bifulco CB. J Immunother Cancer. 2025 Jan 8; 2025 Jan 8. PMID: 39779210.
• Racial Disparities in Perioperative Outcomes for Patients With Head and Neck Cancer.Fereydooni S, Valdez C, Williams LC, Verma A, Judson B. Head Neck. 2024 Dec 23; 2024 Dec 23. PMID: 39713894.
• Seven years of Non-invasive Follicular Thyroid Neoplasm with Papillary-like Nuclear Features (NIFTP): Rate of Acceptance and Variation of Diagnostic Approaches Across Different Continents.Williams MD, Liu Z, Rossi ED, Agarwal S, Ryška A, Ghuzlan AA, Bychkov A, Baloch Z, Chernock R, Chiosea SL, Cipriani NA, Erkilic S, Fridman M, Hang JF, Harahap AS, Jung CK, Kakudo K, Khalil M, Khanafshar E, Kumarasinghe P, Lloyd R, Nguyen TP, Ocal IT, Prasad ML, Pusztaszeri M, Rana C, Sadow P, Sajed DP, Seethala R, Tallini G, Vuong HG, Yegen G, LiVolsi VA, Nikiforov YE. J Clin Endocrinol Metab. 2024 Dec 18. PMID: 38874075.
• OST Catalytic Subunit Redundancy Enables Therapeutic Targeting of N-Glycosylation.Baro M, Lee H, Kelley V, Lou R, Phoomak C, Politi K, Zeiss CJ, Van Zandt M, Contessa JN. bioRxiv. 2024 Dec 5; 2024 Dec 5. PMID: 39677793.
• The analytical and clinical validity of AI algorithms to score TILs in TNBC: can we use different machine learning models interchangeably?Vidal JM, Tsiknakis N, Staaf J, Bosch A, Ehinger A, Nimeus E, Salgado R, Bai Y, Rimm DL, Hartman J, Acs B. EClinicalMedicine. 2024 Dec; 2024 Nov 15. PMID: 39634035.
• Absence of the dolichol synthesis gene DHRSX leads to N-glycosylation defects in Lec5 and Lec9 Chinese hamster ovary cells.Kentache T, Althoff CR, Caligiore F, Souche E, Schulz C, Graff J, Pieters E, Stanley P, Contessa JN, Van Schaftingen E, Matthijs G, Foulquier F, Bommer GT, Wilson MP. J Biol Chem. 2024 Dec; 2024 Oct 10. PMID: 39395802.
• Vaping and tumor metastasis: current insights and progress.Xi Y, Yang L, Burtness B, Wang H. Cancer Metastasis Rev. 2024 Nov 25; 2024 Nov 25. PMID: 39581913.
• EIF1AX mutation in thyroid nodules: a histopathologic analysis of 56 cases in the context of institutional practices.Abi-Raad R, Xu B, Gilani S, Ghossein RA, Prasad ML. Virchows Arch. 2024 Nov; 2024 Sep 3. PMID: 39225726.
• Predisposing, Enabling, and Need Factors Driving Palliative Care Use in Head and Neck Cancer.Fereydooni S, Valdez C, Williams L, Malik D, Mehra S, Judson B. Otolaryngol Head Neck Surg. 2024 Oct; 2024 May 26. PMID: 38796734.
• Laryngeal rare benign non-epithelial tumors and sarcomas emphasizing on chondrosarcomas: A literature review and a case presentation.Vageli DP, Doukas PG, Paraskeva AN, Zacharouli K, Judson BL, Ioannou M. Pathol Res Pract. 2024 Sep; 2024 Jul 30. PMID: 39116572.
• Pembrolizumab Plus Carboplatin and Paclitaxel as First-Line Therapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-B10): A Single-Arm Phase IV Trial.Dzienis M, Cundom J, Fuentes CS, Spreafico A, Nordlinger M, Pastor AV, Alesi E, Neki A, Fung AS, Figueiredo Lima IP, Oppelt P, da Cunha Junior GF, Burtness B, Franke FA, Tseng JE, Joshi A, McCarthy J, Swaby R, Sidi Y, Gumuscu B, Naicker N, de Castro G Jr. J Clin Oncol. 2024 Sep 1; 2024 Jul 22. PMID: 39038265.
• Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer With a High-Sensitivity Assay.Liu M, Vathiotis I, Robbins CJ, Chan NNN, Moutafi M, Burela S, Xirou V, Schalper KA, Herbst RS, Syrigos K, Rimm DL. Mod Pathol. 2024 Sep; 2024 Jul 2. PMID: 38964502.
• Association of Medical School Gap Year Research and Degree Programs With Otolaryngology Interview and Match Outcomes.Boyi T, Benjamin WJ, Lenze NR, Brenner MJ, Mihalic AP, Kupfer RA, Judson BL, Lee YH. Ann Otol Rhinol Laryngol. 2024 Sep; 2024 Jun 17. PMID: 38887016.
• BCAM (basal cell adhesion molecule) protein expression in different tumor populations.Burela S, He M, Trontzas IP, Gavrielatou N, Schalper KA, Langermann S, Flies DB, Rimm DL, Aung TN. Discov Oncol. 2024 Aug 29; 2024 Aug 29. PMID: 39207605.
• Spatially Informed Gene Signatures for Response to Immunotherapy in Melanoma.Aung TN, Warrell J, Martinez-Morilla S, Gavrielatou N, Vathiotis I, Yaghoobi V, Kluger HM, Gerstein M, Rimm DL. Clin Cancer Res. 2024 Aug 15. PMID: 38837895.
• Identifying Opportunities to Deliver High-Quality Cancer Care Across a Health System: A Clinical Responsibility.Shah HP, Cohen O, Bourdillon AT, Burtness BA, Boffa DJ, Young M, Judson BL, Mehra S. Otolaryngol Head Neck Surg. 2024 Aug; 2024 Apr 12. PMID: 38606669.
• Single-cell analysis reveals transcriptional dynamics in healthy primary parathyroid tissue.Venkat A, Carlino MJ, Lawton BR, Prasad ML, Amodio M, Gibson CE, Zeiss CJ, Youlten SE, Krishnaswamy S, Krause DS. Genome Res. 2024 Jul 23; 2024 Jul 23. PMID: 38977309.
• The N-glycosylation defect in Lec5 and Lec9 CHO cells is caused by absence of the DHRSX gene.Kentache T, Althoff CR, Caligiore F, Souche E, Schulz C, Graff J, Pieters E, Stanley P, Contessa JN, Van Schaftingen E, Matthijs G, Foulquier F, Bommer GT, Wilson MP. bioRxiv. 2024 Jun 18; 2024 Jun 18. PMID: 38948797.
• High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC).Moutafi MK, Bates KM, Aung TN, Milian RG, Xirou V, Vathiotis IA, Gavrielatou N, Angelakis A, Schalper KA, Salichos L, Rimm DL. J Immunother Cancer. 2024 Jun 10; 2024 Jun 10. PMID: 38857914.
• Novel non-invasive molecular signatures for oral cavity cancer, by whole transcriptome and small non-coding RNA sequencing analyses: Predicted association with PI3K/AKT/mTOR pathway.Vageli DP, Doukas PG, Townsend JP, Pickering C, Judson BL. Cancer Med. 2024 Jun. PMID: 38819439.
• Multiplexable and Scalable Aqueous Synthesis Platform for Oleate-Based, Bilayer-Coated Gold Nanoparticles.Backhaus A, Albrecht J, Alzhanova G, Long A, Arnold W, Lee J, Tse HY, Su TT, Cruz-Gomez S, Lee SSS, Menges F, Parent LR, Ratjen L, Burtness B, Fortner JD, Zimmerman JB. Small. 2024 Jun; 2024 Feb 20. PMID: 38377304.
• Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database.Baliga S, Abou-Foul AK, Parente P, Szturz P, Thariat J, Shreenivas A, Nankivell P, Bertolini F, Biau J, Blakaj D, Brennan S, Brunet A, De Oliveira TB, Burtness B, Maseda AC, Chow VL, Chua ML, de Ridder M, Garikipati S, Hanai N, Ho FCH, Huang SH, Kiyota N, Klinghammer K, Kowalski LP, Kwong DL, McDowell LJ, Merlano MC, Nair S, Economopoulou P, Overgaard J, Psyrri A, Tribius S, Waldron J, Yom SS, Mehanna H. Eur J Cancer. 2024 May; 2024 Mar 30. PMID: 38579517.
• Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL. Lancet Oncol. 2024 May; 2024 Mar 29. PMID: 38561010.
• An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.Xirou V, Moutafi M, Bai Y, Nwe Aung T, Burela S, Liu M, Kimple RJ, Shabbir Ahmed F, Schultz B, Flieder D, Connolly DC, Psyrri A, Burtness B, Rimm DL. Oral Oncol. 2024 May; 2024 Mar 27. PMID: 38547779.
• Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.Haider SP, Zeevi T, Sharaf K, Gross M, Mahajan A, Kann BH, Judson BL, Prasad ML, Burtness B, Aboian M, Canis M, Reichel CA, Baumeister P, Payabvash S. J Nucl Med. 2024 May 1; 2024 May 1. PMID: 38514087.
• Molecular Genetics Augment Cytopathologic Evaluation and Surgical Planning of Pediatric Thyroid Nodules.Spaulding SL, Maayah M, Dinauer CA, Prasad M, Darbinyan A, Morotti R, Christison-Lagay ER. J Pediatr Surg. 2024 May; 2024 Jan 7. PMID: 38246817.
• In Vivo Verification of Electron Paramagnetic Resonance Biodosimetry Using Patients Undergoing Radiation Therapy Treatment.Draeger E, Roberts K, Decker RD, Bahar N, Wilson LD, Contessa J, Husain Z, Williams BB, Flood AB, Swartz HM, Carlson DJ. Int J Radiat Oncol Biol Phys. 2024 May 1; 2023 Dec 10. PMID: 38072322.
• Positive selection CRISPR screens reveal a druggable pocket in an oligosaccharyltransferase required for inflammatory signaling to NF-κB.Lampson BL, Ramίrez AS, Baro M, He L, Hegde M, Koduri V, Pfaff JL, Hanna RE, Kowal J, Shirole NH, He Y, Doench JG, Contessa JN, Locher KP, Kaelin WG Jr. Cell. 2024 Apr 25. PMID: 38670073.
• De-Escalated Therapy and Early Treatment of Recurrences in HPV-Associated Head and Neck Cancer: The Potential for Biomarkers to Revolutionize Personalized Therapy.Yarbrough WG, Schrank TP, Burtness BA, Issaeva N. Viruses. 2024 Mar 29; 2024 Mar 29. PMID: 38675879.
• Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.Su DG, Schoenfeld DA, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm DL, Khan SA, Halaban R, Kluger HM, Olino K, Galan A, Clune J. J Immunother Cancer. 2024 Mar 21; 2024 Mar 21. PMID: 38519058.
• Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA Jr, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A. Eur J Cancer. 2024 Mar; 2024 Jan 11. PMID: 38295556.
• Image-based multiplex immune profiling of cancer tissues: translational implications. A report of the International Immuno-oncology Biomarker Working Group on Breast Cancer.Jahangir CA, Page DB, Broeckx G, Gonzalez CA, Burke C, Murphy C, Reis-Filho JS, Ly A, Harms PW, Gupta RR, Vieth M, Hida AI, Kahila M, Kos Z, van Diest PJ, Verbandt S, Thagaard J, Khiroya R, Abduljabbar K, Acosta Haab G, Acs B, Adams S, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Burgues O, Chardas A, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Fernandez-Martín C, Fineberg S, Fox SB, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hewitt S, Horlings HM, Husain Z, Irshad S, Janssen EA, Kataoka TR, Kawaguchi K, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Akturk G, Scott E, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Kharidehal D, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rajpoot NM, Rapoport BL, Rau TT, Ribeiro JM, Rimm D, Vincent-Salomon A, Saltz J, Sayed S, Hytopoulos E, Mahon S, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, Verghese GE, Viale G, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Specht Stovgaard E, Salgado R, Gallagher WM, Rahman A. J Pathol. 2024 Mar; 2024 Jan 17. PMID: 38230434.
• High-Plex Assessment of Biomarkers in Tumors.Aung TN, Bates KM, Rimm DL. Mod Pathol. 2024 Mar; 2024 Jan 12. PMID: 38219953.
• A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305.Argiris A, Flamand Y, Savvides P, Johnson JM, Vathiotis I, Levine M, Li S, Forastiere AA, Burtness B. Eur J Cancer. 2024 Mar; 2023 Dec 29. PMID: 38215573.
• Correlation of HER2 Protein Level With mRNA Level Quantified by RNAscope in Breast Cancer.Li X, Lee JH, Gao Y, Zhang J, Bates KM, Rimm DL, Zhang H, Smith GH, Lawson D, Meisel J, Chang J, Huo L. Mod Pathol. 2024 Feb; 2023 Dec 20. PMID: 38135153.
• Automated scoring of tumor-infiltrating lymphocytes informs risk of death from thin melanoma: A nested case-case study.Tan SX, Aung TN, Claeson M, Acs B, Zhou C, Brown S, Lambie D, Baade PD, Pandeya N, Soyer HP, Smithers BM, Whiteman DC, Rimm DL, Khosrotehrani K. J Am Acad Dermatol. 2024 Jan; 2023 Sep 19. PMID: 37730017.
• ER chaperones use a protein folding and quality control glyco-code.Guay KP, Ke H, Canniff NP, George GT, Eyles SJ, Mariappan M, Contessa JN, Gershenson A, Gierasch LM, Hebert DN. Mol Cell. 2023 Dec 21; 2023 Dec 4. PMID: 38052210.
• A Novel Saliva and Serum miRNA Panel as a Potential Useful Index for Oral Cancer and the Association of miR-21 with Smoking History: a Pilot Study.Vageli DP, Doukas PG, Shah R, Boyi T, Liu C, Judson BL. Cancer Prev Res (Phila). 2023 Dec 1. PMID: 37683274.
• Association of Age and Frailty With 30-Day Outcomes Among Patients Undergoing Oral Cavity Cancer Surgery.Boyi T, Williams LC, Kafle S, Roche AM, Judson BL. Otolaryngol Head Neck Surg. 2023 Dec; 2023 Aug 18. PMID: 37595108.
• Over-The-Counter Hearing Aids: Trends in Information-Seeking Behavior.Panth N, Shah R, Judson B, Schwartz N. Otolaryngol Head Neck Surg. 2023 Dec; 2023 Jun 27. PMID: 37365970.
• Improving Post-procedure Outcomes With Clinical Care Pathway for Enteral Access.Miller SM, Abou-Azar S, Owusu KA, Judson BL, Rhodes D, Morton JM. Am Surg. 2023 Dec; 2023 May 19. PMID: 37203186.
• Emerging Prognostic and Predictive Significance of Stress Keratin 17 in HPV-Associated and Non HPV-Associated Human Cancers: A Scoping Review.Lozar T, Wang W, Gavrielatou N, Christensen L, Lambert PF, Harari PM, Rimm DL, Burtness B, Grasic Kuhar C, Carchman EH. Viruses. 2023 Nov 25; 2023 Nov 25. PMID: 38140561.
• Radiotherapy Plus Cisplatin With or Without Lapatinib for Non-Human Papillomavirus Head and Neck Carcinoma: A Phase 2 Randomized Clinical Trial.Wong SJ, Torres-Saavedra PA, Saba NF, Shenouda G, Bumpous JM, Wallace RE, Chung CH, El-Naggar AK, Gwede CK, Burtness B, Tennant PA, Dunlap NE, Redman R, Stokes WA, Rudra S, Mell LK, Sacco AG, Spencer SA, Nabell L, Yao M, Cury FL, Mitchell DL, Jones CU, Firat S, Contessa JN, Galloway T, Currey A, Harris J, Curran WJ Jr, Le QT. JAMA Oncol. 2023 Nov 1. PMID: 37768670.
• Extra imaging beyond NCCN surveillance guidelines is cost effective for HPV- but not HPV+ oropharyngeal cancer.Shah R, Tyagi S, Liu C, Judson B. Oral Oncol. 2023 Nov; 2023 Sep 4. PMID: 37672950.
• The Representation of Surgery in Oncology Clinical Trials: 2001 to 2022.Shah R, Boffa D, Khan S, Judson B. Ann Surg Oncol. 2023 Nov; 2023 Aug 9. PMID: 37556010.
• Stress Keratin 17 Is a Predictive Biomarker Inversely Associated with Response to Immune Check-Point Blockade in Head and Neck Squamous Cell Carcinomas and Beyond.Lozar T, Laklouk I, Golfinos AE, Gavrielatou N, Xu J, Flynn C, Keske A, Yu M, Bruce JY, Wang W, Grasic Kuhar C, Bailey HH, Harari PM, Dinh HQ, Rimm DL, Hu R, Lambert PF, Fitzpatrick MB. Cancers (Basel). 2023 Oct 9; 2023 Oct 9. PMID: 37835599.
• The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership.Snyder RA, Burtness B, Cho M, Del Rivero J, Doroshow DB, Hitchcock KE, Kalyan A, Kim CA, Lukovic J, Parikh AR, Sanford NN, Singh B, Shen C, Shroff RT, Vijayvergia N, Goodman KA, Kunz PL. J Natl Cancer Inst. 2023 Oct 9. PMID: 37364007.
• Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy.Martinez-Morilla S, Moutafi M, Fernandez AI, Jessel S, Divakar P, Wong PF, Garcia-Milian R, Schalper KA, Kluger HM, Rimm DL. Oncoimmunology. 2023; 2023 Sep 27. PMID: 37781235.
• Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial.Stockton S, Catalano P, Cohen SJ, Burtness BA, Mitchell EP, Dotan E, Lubner SJ, Kumar P, Mulcahy MF, Fisher GA, Crandall TL, Benson A. Oncologist. 2023 Sep 7. PMID: 37104870.
• Classification of Breast Cancer According to ERBB2 Immunohistochemistry Scores.Robbins CJ, Fernandez AI, Rimm DL. JAMA Oncol. 2023 Sep 1. PMID: 37498606.
• Mammalian SWI/SNF chromatin remodeling complexes promote tyrosine kinase inhibitor resistance in EGFR-mutant lung cancer.de Miguel FJ, Gentile C, Feng WW, Silva SJ, Sankar A, Exposito F, Cai WL, Melnick MA, Robles-Oteiza C, Hinkley MM, Tsai JA, Hartley AV, Wei J, Wurtz A, Li F, Toki MI, Rimm DL, Homer R, Wilen CB, Xiao AZ, Qi J, Yan Q, Nguyen DX, Jänne PA, Kadoch C, Politi KA. Cancer Cell. 2023 Aug 14; 2023 Aug 3. PMID: 37541244.
• Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer.Moutafi M, Koliou GA, Papaxoinis G, Economopoulou P, Kotsantis I, Gkotzamanidou M, Anastasiou M, Pectasides D, Kyrodimos E, Delides A, Giotakis E, Papadimitriou NG, Panayiotides IG, Perisanidis C, Fernandez AI, Xirou V, Poulios C, Gagari E, Yaghoobi V, Gavrielatou N, Shafi S, Aung TN, Kougioumtzopoulou A, Kouloulias V, Palialexis K, Gkolfinopoulos S, Strati A, Lianidou E, Fountzilas G, Rimm DL, Foukas PG, Psyrri A. Cancer Res Commun. 2023 Aug; 2023 Aug 10. PMID: 37575280.
• Noncanonical HPV carcinogenesis drives radiosensitization of head and neck tumors.Schrank TP, Kothari A, Weir WH, Stepp WH, Rehmani H, Liu X, Wang X, Sewell A, Li X, Tasoulas J, Kim S, Yarbrough G, Xie Y, Flamand Y, Marur S, Hayward MC, Wu D, Burtness B, Anderson KS, Baldwin AS, Yarbrough WG, Issaeva N. Proc Natl Acad Sci U S A. 2023 Aug 8; 2023 Jul 31. PMID: 37523561.
• Prognostic value of absolute lymphocyte count in oral cavity squamous cell carcinoma.Shah R, Liu C, Shah HP, Judson BL. Laryngoscope Investig Otolaryngol. 2023 Aug; 2023 Jun 15. PMID: 37621277.
• Pitfalls in machine learning-based assessment of tumor-infiltrating lymphocytes in breast cancer: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.Thagaard J, Broeckx G, Page DB, Jahangir CA, Verbandt S, Kos Z, Gupta R, Khiroya R, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Amgad M, Azmoudeh-Ardalan F, Badve S, Baharun NB, Balslev E, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Chardas A, Chon U Cheang M, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dahl AB, Dantas Portela FL, Deman F, Demaria S, Doré Hansen J, Dudgeon SN, Ebstrup T, Elghazawy M, Fernandez-Martín C, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hart SN, Hartman J, Hauberg S, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Roslind A, Vincent-Salomon A, Salto-Tellez M, Saltz J, Sayed S, Scott E, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Fineberg S, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Zin RM, Adams S, Bartlett J, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E. J Pathol. 2023 Aug; 2023 Aug 23. PMID: 37608772.
• Spatial analyses of immune cell infiltration in cancer: current methods and future directions: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.Page DB, Broeckx G, Jahangir CA, Verbandt S, Gupta RR, Thagaard J, Khiroya R, Kos Z, Abduljabbar K, Acosta Haab G, Acs B, Akturk G, Almeida JS, Alvarado-Cabrero I, Azmoudeh-Ardalan F, Badve S, Baharun NB, Bellolio ER, Bheemaraju V, Blenman KR, Botinelly Mendonça Fujimoto L, Bouchmaa N, Burgues O, Cheang MCU, Ciompi F, Cooper LA, Coosemans A, Corredor G, Dantas Portela FL, Deman F, Demaria S, Dudgeon SN, Elghazawy M, Ely S, Fernandez-Martín C, Fineberg S, Fox SB, Gallagher WM, Giltnane JM, Gnjatic S, Gonzalez-Ericsson PI, Grigoriadis A, Halama N, Hanna MG, Harbhajanka A, Hardas A, Hart SN, Hartman J, Hewitt S, Hida AI, Horlings HM, Husain Z, Hytopoulos E, Irshad S, Janssen EA, Kahila M, Kataoka TR, Kawaguchi K, Kharidehal D, Khramtsov AI, Kiraz U, Kirtani P, Kodach LL, Korski K, Kovács A, Laenkholm AV, Lang-Schwarz C, Larsimont D, Lennerz JK, Lerousseau M, Li X, Ly A, Madabhushi A, Maley SK, Manur Narasimhamurthy V, Marks DK, McDonald ES, Mehrotra R, Michiels S, Minhas FUAA, Mittal S, Moore DA, Mushtaq S, Nighat H, Papathomas T, Penault-Llorca F, Perera RD, Pinard CJ, Pinto-Cardenas JC, Pruneri G, Pusztai L, Rahman A, Rajpoot NM, Rapoport BL, Rau TT, Reis-Filho JS, Ribeiro JM, Rimm D, Vincent-Salomon A, Salto-Tellez M, Saltz J, Sayed S, Siziopikou KP, Sotiriou C, Stenzinger A, Sughayer MA, Sur D, Symmans F, Tanaka S, Taxter T, Tejpar S, Teuwen J, Thompson EA, Tramm T, Tran WT, van der Laak J, van Diest PJ, Verghese GE, Viale G, Vieth M, Wahab N, Walter T, Waumans Y, Wen HY, Yang W, Yuan Y, Adams S, Bartlett JMS, Loibl S, Denkert C, Savas P, Loi S, Salgado R, Specht Stovgaard E. J Pathol. 2023 Aug; 2023 Aug 23. PMID: 37608771.
• Immune dysfunction revealed by digital spatial profiling of immuno-oncology markers in progressive stages of renal cell carcinoma and in brain metastases.Schoenfeld DA, Moutafi M, Martinez S, Djureinovic D, Merkin RD, Adeniran A, Braun DA, Signoretti S, Choueiri TK, Parisi F, Hurwitz M, Rimm DL, Wei W, Jilaveanu L, Kluger HM. J Immunother Cancer. 2023 Aug. PMID: 37586773.
• Subsets of IFN Signaling Predict Response to Immune Checkpoint Blockade in Patients with Melanoma.Horowitch B, Lee DY, Ding M, Martinez-Morilla S, Aung TN, Ouerghi F, Wang X, Wei W, Damsky W, Sznol M, Kluger H, Rimm DL, Ishizuka JJ. Clin Cancer Res. 2023 Aug 1. PMID: 37233452.
• Randomized Phase II Trial of Ficlatuzumab With or Without Cetuximab in Pan-Refractory, Recurrent/Metastatic Head and Neck Cancer.Bauman JE, Saba NF, Roe D, Bauman JR, Kaczmar J, Bhatia A, Muzaffar J, Julian R, Wang S, Bearelly S, Baker A, Steuer C, Giri A, Burtness B, Centuori S, Caulin C, Klein R, Saboda K, Obara S, Chung CH. J Clin Oncol. 2023 Aug 1; 2023 Mar 28. PMID: 36977289.
• Trends in Residency Applicant Volume in Otolaryngology-Head and Neck Surgery and Peer Specialties.Bourdillon AT, Salehi PP, Wride M, Salehi P, Torabi S, Heiser A, Shah HP, Azizzadeh B, Judson B, Lee YH. Ann Otol Rhinol Laryngol. 2023 Aug; 2022 Aug 29. PMID: 36031814.
• Autologous humanized PDX modeling for immuno-oncology recapitulates features of the human tumor microenvironment.Chiorazzi M, Martinek J, Krasnick B, Zheng Y, Robbins KJ, Qu R, Kaufmann G, Skidmore Z, Juric M, Henze LA, Brösecke F, Adonyi A, Zhao J, Shan L, Sefik E, Mudd J, Bi Y, Goedegebuure SP, Griffith M, Griffith O, Oyedeji A, Fertuzinhos S, Garcia-Milian R, Boffa D, Detterbeck F, Dhanasopon A, Blasberg J, Judson B, Gettinger S, Politi K, Kluger Y, Palucka K, Fields RC, Flavell RA. J Immunother Cancer. 2023 Jul. PMID: 37487666.
• Deep learning-based scoring of tumour-infiltrating lymphocytes is prognostic in primary melanoma and predictive to PD-1 checkpoint inhibition in melanoma metastases.Chatziioannou E, Roßner J, Aung TN, Rimm DL, Niessner H, Keim U, Serna-Higuita LM, Bonzheim I, Kuhn Cuellar L, Westphal D, Steininger J, Meier F, Pop OT, Forchhammer S, Flatz L, Eigentler T, Garbe C, Röcken M, Amaral T, Sinnberg T. EBioMedicine. 2023 Jul; 2023 Jun 7. PMID: 37295047.
• Multiplex Immunohistochemistry and Immunofluorescence: A Practical Update for Pathologists.Harms PW, Frankel TL, Moutafi M, Rao A, Rimm DL, Taube JM, Thomas D, Chan MP, Pantanowitz L. Mod Pathol. 2023 Jul; 2023 Apr 25. PMID: 37105494.
• Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test.Fernandez AI, Gaule P, Rimm DL. Mod Pathol. 2023 Jul; 2023 Mar 15. PMID: 36925070.
• Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer.Barrera C, Corredor G, Viswanathan VS, Ding R, Toro P, Fu P, Buzzy C, Lu C, Velu P, Zens P, Berezowska S, Belete M, Balli D, Chang H, Baxi V, Syrigos K, Rimm DL, Velcheti V, Schalper K, Romero E, Madabhushi A. NPJ Precis Oncol. 2023 Jun 1; 2023 Jun 1. PMID: 37264091.
• Evaluating the medical management of locally advanced and metastatic basal cell carcinoma: A single institutional retrospective analysis investigating efficacy, safety, and tolerability.Belzer A, Pach J, Mortlock RD, Clune J, Olino K, Sznol M, Bhatia A, Burtness B, Christensen S, Leventhal JS. JAAD Int. 2023 Jun; 2023 Feb 26. PMID: 37252181.
• Screening for extranodal extension in HPV-associated oropharyngeal carcinoma: evaluation of a CT-based deep learning algorithm in patient data from a multicentre, randomised de-escalation trial.Kann BH, Likitlersuang J, Bontempi D, Ye Z, Aneja S, Bakst R, Kelly HR, Juliano AF, Payabvash S, Guenette JP, Uppaluri R, Margalit DN, Schoenfeld JD, Tishler RB, Haddad R, Aerts HJWL, Garcia JJ, Flamand Y, Subramaniam RM, Burtness BA, Ferris RL. Lancet Digit Health. 2023 Jun; 2023 Apr 21. PMID: 37087370.
• Grading system for medullary thyroid carcinoma; an institutional experience.Podany P, Meiklejohn K, Garritano J, Holt EH, Barbieri A, Prasad M, Gilani SM. Ann Diagn Pathol. 2023 Jun; 2023 Jan 31. PMID: 36736129.
• Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial.Fanucci KA, Bai Y, Pelekanou V, Nahleh ZA, Shafi S, Burela S, Barlow WE, Sharma P, Thompson AM, Godwin AK, Rimm DL, Hortobagyi GN, Liu Y, Wang L, Wei W, Pusztai L, Blenman KRM. NPJ Breast Cancer. 2023 May 13; 2023 May 13. PMID: 37179362.
• Assessment of the Impact of Alternative Fixatives on HER2 Detection in Breast Cancer and Gastric Cancer Tumor Specimens.Feng W, Inoue R, Kuwata T, Niikura N, Fujii S, Kumaki N, Honda K, Xu LA, Goetz A, Gaule P, Cogswell J, Rimm DL, McGee R. Appl Immunohistochem Mol Morphol. 2023 May-Jun 01; 2023 Apr 24. PMID: 37093713.
• Multi-Institutional Study of Pathologist Reading of the Programmed Cell Death Ligand-1 Combined Positive Score Immunohistochemistry Assay for Gastric or Gastroesophageal Junction Cancer.Fernandez AI, Robbins CJ, Gaule P, Agostini-Vulaj D, Anders RA, Bellizzi AM, Chen W, Chen ZE, Gopal P, Zhao L, Lisovsky M, Liu X, Shia J, Wang H, Yang Z, McCann L, Chan YG, Weidler J, Bates M, Zhang X, Rimm DL. Mod Pathol. 2023 May; 2023 Feb 13. PMID: 36889057.
• Diagnosis of acinic cell carcinoma of the salivary gland on cytology specimens: Role of NOR-1 (NR4A3) immunohistochemistry.Meiklejohn K, Hrones M, Wang M, Prasad ML, Cai G, Adeniran A, Gilani SM. Cytopathology. 2023 May; 2023 Mar 8. PMID: 36825365.
• Top advances of the year: Head and neck cancer.Verma A, Burtness B. Cancer. 2023 May 1; 2023 Jan 24. PMID: 36692372.
• The Role of PARP-1 and NF-κB in Bile-Induced DNA Damage and Oncogenic Profile in Hypopharyngeal Cells.Doukas PG, Vageli DP, Judson BL. Laryngoscope. 2023 May; 2022 Jul 6. PMID: 35791892.
• First-Line Nivolumab Plus Ipilimumab in Recurrent/Metastatic Head and Neck Cancer-What Happened?Burtness B. J Clin Oncol. 2023 Apr 20; 2023 Mar 6. PMID: 36877893.
• Human Immunodeficiency Virus Is Associated With Poor Overall Survival Among Patients With Head and Neck Cancer.Salahuddin S, Cohen O, Wu M, Perez Irizarry J, Vega T, Gan G, Deng Y, Isaeva N, Prasad M, Schalper KA, Mehra S, Yarbrough WG, Emu B. Clin Infect Dis. 2023 Apr 17. PMID: 36520995.
• Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma.Gavrielatou N, Vathiotis I, Aung TN, Shafi S, Burela S, Fernandez AI, Moutafi M, Burtness B, Economopoulou P, Anastasiou M, Foukas P, Psyrri A, Rimm DL. Cancer Res Commun. 2023 Apr; 2023 Apr 11. PMID: 37057033.
• Outcomes Stratification of Head and Neck Cancer Using Pre- and Post-treatment DNA Methylation From Peripheral Blood.Qian DC, Ulrich BC, Peng G, Zhao H, Conneely KN, Miller AH, Bruner DW, Eldridge RC, Wommack EC, Higgins KA, Shin DM, Saba NF, Smith AK, Burtness B, Park HS, Stokes WA, Beitler JJ, Xiao C. Int J Radiat Oncol Biol Phys. 2023 Apr 1; 2022 Nov 21. PMID: 36410685.
• Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non-small Cell Lung Cancer.Aung TN, Gavrielatou N, Vathiotis IA, Fernandez AI, Shafi S, Yaghoobi V, Burela S, MacNeil T, Ahmed FS, Myint H, Flies DB, Langermann S, Rimm DL. Cancer Res Commun. 2023 Mar; 2023 Mar 21. PMID: 36960400.
• Signal recognition particle receptor-β (SR-β) coordinates cotranslational N-glycosylation.Phoomak C, Rinis N, Baro M, Shrimal S, Bennett D, Shaffer SA, Lehrman M, Gilmore R, Contessa JN. Sci Adv. 2023 Mar 17; 2023 Mar 15. PMID: 36921042.
• Spatial characterization and quantification of CD40 expression across cancer types.Bates KM, Vathiotis I, MacNeil T, Ahmed FS, Aung TN, Katlinskaya Y, Bhattacharya S, Psyrri A, Yea S, Parkes A, Sadraei NH, Roychoudhury S, Rimm DL, Gavrielatou N. BMC Cancer. 2023 Mar 9; 2023 Mar 9. PMID: 36894898.
• Impact of radiotherapy delay following biopsy for patients with unresected glioblastoma.Gao S, Jin L, Moliterno J, Corbin ZA, Bindra RS, Contessa JN, Yu JB, Park HS. J Neurosurg. 2023 Mar 1; 2022 Jul 29. PMID: 35907197.
• Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update.Bhatia A, Burtness B. Drugs. 2023 Feb; 2023 Jan 16. PMID: 36645621.
• Multicenter analysis of stereotactic radiosurgery for multiple brain metastases from EGFR and ALK driven non-small cell lung cancer.Wandrey NE, Gao D, Robin TP, Contessa JN, Singh C, Chiang V, Li J, Chen A, Wang Y, Sheehan JP, Dutta SW, Weiss SE, Paly J, Rusthoven CG. Lung Cancer. 2023 Feb; 2022 Dec 12. PMID: 36641932.
• Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.Harrington KJ, Burtness B, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Lin J, Gumuscu B, Swaby RF, Rischin D. J Clin Oncol. 2023 Feb 1; 2022 Oct 11. PMID: 36219809.
• Resident Burnout and Well-being in Otolaryngology and Other Surgical Specialties: Strategies for Change.Shah HP, Salehi PP, Ihnat J, Kim DD, Salehi P, Judson BL, Azizzadeh B, Lee YH. Otolaryngol Head Neck Surg. 2023 Feb. PMID: 35133919.
• Author Correction: Head and neck squamous cell carcinoma.Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Nat Rev Dis Primers. 2023 Jan 19; 2023 Jan 19. PMID: 36658129.
• Multi-institutional Assessment of Pathologist Scoring HER2 Immunohistochemistry.Robbins CJ, Fernandez AI, Han G, Wong S, Harigopal M, Podoll M, Singh K, Ly A, Kuba MG, Wen H, Sanders MA, Brock J, Wei S, Fadare O, Hanley K, Jorns J, Snir OL, Yoon E, Rabe K, Soong TR, Reisenbichler ES, Rimm DL. Mod Pathol. 2023 Jan. PMID: 36788069.
• The Pathologists' Conundrum.Rimm DL, Dacic S, Schnitt SJ. Arch Pathol Lab Med. 2023 Jan 1. PMID: 36577091.